BioCardia, Inc. Common Stock (BCDA) Stock Price

BCDAStock

$1.15−41.33%52W

Market Cap$17.41M

P/E—

PEG Ratio—

Div yield—

Beta0.61

BCDA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-13.22%

Price vs S&P 500 (4W)36.81%

VGM Score33.42

Book Value / Share (Quarterly)$0.08

P/TBV (Annual)51.82x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-61.55%

Cash Flow / Share (Quarterly)$-0.68

Price vs S&P 500 (YTD)-20.82%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-1985.85%

EPS (TTM)$-0.80

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-0.80

Revenue Growth (5Y)-39.41%

EPS (Annual)$-1.23

ROI (Annual)-919.33%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-5649.05%

Cash / Share (Quarterly)$0.09

ROA (Last FY)-241.08%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)-462.40%

Operating Margin (TTM)-1997.45%

Cash Flow / Share (Annual)$-0.69

P/B Ratio14.72x

P/B Ratio (Quarterly)14.82x

Net Income / Employee (Annual)$-484,000

EV / Revenue (TTM)28.36x

Net Interest Coverage (TTM)-2.48x

ROA (TTM)-261.66%

EV / EBITDA (TTM)5.22x

EPS Incl Extra (Annual)$-1.23

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.35x

3-Month Avg Trading Volume2.23M

52-Week Price Return-41.33%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.75

P/S Ratio (Annual)227.11x

Asset Turnover (Annual)0.02x

52-Week High$2.29

Operating Margin (5Y Avg)-5673.79%

EPS Excl Extra (Annual)$-1.23

CapEx CAGR (5Y)-25.25%

Tangible BV CAGR (5Y)-15.15%

26-Week Price Return-1.29%

Quick Ratio (Annual)1.03x

13-Week Price Return25.44%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.41x

Enterprise Value$12.22M

Revenue / Share Growth (5Y)-30.04%

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)-24.84%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)5.14x

Pretax Margin (Annual)-13700.00%

Cash / Share (Annual)$0.23

3-Month Return Std Dev86.61%

Gross Margin (5Y Avg)43.27%

Net Income / Employee (TTM)$-370,100

ROE (Last FY)-919.33%

Net Interest Coverage (Annual)-93.75x

EPS Basic Excl Extra (Annual)$-1.23

P/FCF (TTM)39.92x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.80

Receivables Turnover (Annual)0.00x

ROI (TTM)-221.68%

P/S Ratio (TTM)30.56x

Pretax Margin (5Y Avg)-5649.05%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.03

Price vs S&P 500 (52W)-59.88%

Year-to-Date Return-8.00%

5-Day Price Return8.49%

EPS Normalized (Annual)$-1.23

ROA (5Y Avg)-208.75%

Net Profit Margin (Annual)-13700.00%

Month-to-Date Return39.53%

Cash Flow / Share (TTM)$-0.62

EBITD / Share (Annual)$-1.24

Operating Margin (Annual)-13794.83%

ROI (5Y Avg)-462.40%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.80

P/TBV (Quarterly)24.70x

P/B Ratio (Annual)14.82x

Inventory Turnover (TTM)12.00x

Pretax Margin (TTM)-1985.85%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)23.48%

Beta0.61x

P/FCF (Annual)39.92x

Revenue / Share (TTM)$0.00

ROE (TTM)-221.68%

52-Week Low$0.75

vGradeD

gGradeF

mGradeB

vgmGradeD

BCDA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.19	-$0.13	+31.58%(+$0.06)
Q1 2026	May 15, 2026	-$0.17	-$0.21	-23.53%(-$0.04)
Q4 2025	Mar 24, 2026	-$0.20	-$0.06	+70.00%(+$0.14)
Q3 2025	Nov 12, 2025	-$0.25	-$0.24	+4.00%(+$0.01)
Q2 2025	Aug 11, 2025	-$0.50	-$0.40	+20.00%(+$0.10)

BCDA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCDABioCardia, Inc. Common Stock	D	F	B	$1.15
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About BioCardia, Inc. Common Stock

BioCardia is a clinical-stage company developing cell-based therapeutics for cardiovascular and pulmonary diseases with unmet medical needs. Its CardiAMP platform delivers autologous mononuclear cells derived from bone marrow to treat ischemic heart failure with reduced ejection fraction and refractory angina, while its CardiALLO platform uses off-the-shelf allogeneic mesenchymal stem cells for ischemic heart failure and acute respiratory distress syndrome. CardiALLO is currently enrolling patients in clinical trials.